225942-73-4

Basic information

• Product Name: 3-(4-FORMYL-PHENOXYMETHYL)-BENZOIC ACID METHYL ESTER
• Synonyms: 3-(4-FORMYL-PHENOXYMETHYL)-BENZOIC ACID METHYL ESTER;METHYL 3-[(4-FORMYLPHENOXY)METHYL]BENZOATE
• CAS NO: 225942-73-4
• Molecular Formula: C16H14O4
• Molecular Weight: 270.28
• Mol File: 225942-73-4.mol

Chemical Properties

• Melting Point: 78-81 °C
• Boiling Point: 440.3°C at 760 mmHg
• Flash Point: 196.6°C
• Appearance: /
• Density: 1.208g/cm³
• Vapor Pressure: 5.94E-08mmHg at 25°C
• Refractive Index: 1.594
• CAS DataBase Reference: 3-(4-FORMYL-PHENOXYMETHYL)-BENZOIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4-FORMYL-PHENOXYMETHYL)-BENZOIC ACID METHYL ESTER(225942-73-4)
• EPA Substance Registry System: 3-(4-FORMYL-PHENOXYMETHYL)-BENZOIC ACID METHYL ESTER(225942-73-4)

Safety Data

• Hazardous Substances Data: 225942-73-4(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
3-(4-FORMYL-PHENOXYMETHYL)-BENZOIC ACID METHYL ESTER is utilized as a key intermediate in organic synthesis for the production of various complex organic compounds. Its formyl and phenoxy groups provide versatile points for further chemical reactions, making it a valuable building block in the synthesis of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 3-(4-FORMYL-PHENOXYMETHYL)-BENZOIC ACID METHYL ESTER is employed as a potential bioactive molecule. Its structure may confer pharmacological properties, which can be harnessed in the development of new drugs. Researchers are interested in exploring its potential interactions with biological targets, which could lead to the discovery of novel therapeutic agents.
Used in Pharmaceutical Industry:
3-(4-FORMYL-PHENOXYMETHYL)-BENZOIC ACID METHYL ESTER is used as a starting material or a synthetic intermediate in the pharmaceutical industry for the development of new drugs. Its unique chemical structure may offer specific binding affinities or mechanisms of action that can be exploited in the treatment of various diseases and conditions.
Used in Research and Development:
3-(4-FORMYL-PHENOXYMETHYL)-BENZOIC ACID METHYL ESTER is utilized as a subject of research and development in academic and industrial laboratories. Its exploration can lead to a better understanding of its chemical properties, reactivity, and potential applications, thereby contributing to the advancement of scientific knowledge and the creation of innovative products.

InChI:InChI=1/C16H14O4/c1-19-16(18)14-4-2-3-13(9-14)11-20-15-7-5-12(10-17)6-8-15/h2-10H,11H2,1H3

Upstream product

• 31719-77-4 3-chloromethylbenzoic acid 
• 123-08-0 4-hydroxy-benzaldehyde 
• 34040-63-6 methyl 3-(chloromethyl)benzoate 
• 1129-28-8 3-methoxycarbonylbenzyl bromide 

Downstream Products

• 225942-74-5 methyl (E)-3-<4-(3-methyl-1-butenyl)phenoxymethyl>benzoate 
• 225942-78-9 methyl 3-<4-(2-methyl-2-propenyl)phenoxymethyl>benzoate 

Relevant articles and documents

Novel inhibitors of leukocyte transendothelial migration

Leukocyte transendothelial migration is one of the most important step in launching an inflammatory immune response and chronic inflammation can lead to devastating diseases. Leukocyte migration inhibitors are considered as promising and potentially effective therapeutic agents to treat inflammatory and auto-immune disorders. In this study, based on previous trioxotetrahydropyrimidin based integrin inhibitors that suboptimally blocked leukocyte adhesion, twelve molecules with a modified scaffold were designed, synthesized, and tested in vitro for their capacity to block the transendothelial migration of immune cells. One of the molecules, namely, methyl 4-((2-(tert-butyl)-6-((2,4,6-trioxotetrahydropyrimidin-5(2H)-ylidene) methyl) phenoxy) methyl) benzoate, (compound 12), completely blocked leukocyte transendothelial migration, without any toxic effects on immune or endothelial cells (IC50 = 2.4 μM). In vivo, compound 12 exhibited significant therapeutic effects in inflammatory bowel disease (IBD)/Crohn's disease, multiple sclerosis, fatty liver disease, and rheumatoid arthritis models. A detailed acute and chronic toxicity profile of the lead compound in vivo did not reveal any toxic effects. Such a type of molecule might therefore provide a unique starting point for designing a novel class of leukocyte transmigration blocking agents with broad therapeutic applications in inflammatory and auto-immune pathologies.

Synthesis and structure–activity relationship study of novel quinazolinone-based inhibitors of MurA

MurA is an intracellular bacterial enzyme that is essential for peptidoglycan biosynthesis, and is therefore an important target for antibacterial drug discovery. We report the synthesis, in silico studies and extensive structure–activity relationships of a series of quinazolinone-based inhibitors of MurA from Escherichia coli. 3-Benzyloxyphenylquinazolinones showed promising inhibitory potencies against MurA, in the low micromolar range, with an IC50 of 8?μM for the most potent derivative (58). Furthermore, furan-substituted quinazolinones (38, 46) showed promising antibacterial activities, with MICs from 1?μg/mL to 8?μg/mL, concomitant with their MurA inhibitory potencies. These data represent an important step towards the development of novel antimicrobial agents to combat increasing bacterial resistance.

PHENYLETHYLPYRIDINE DERIVATIVES AS PDE4-INHIBITORS

The invention relates to novel compounds which are inhibitors of the phosphodiesterase 4 (PDE4) enzyme and muscarinic M3 receptor antagonists, methods of preparing such compounds, compositions containing them and therapeutic use thereof.

New 5-benzylidenethiazolidin-4-one inhibitors of bacterial MurD ligase: Design, synthesis, crystal structures, and biological evaluation

Mur ligases (MurC-MurF), a group of bacterial enzymes that catalyze four consecutive steps in the formation of cytoplasmic peptidoglycan precursor, are becoming increasingly adopted as targets in antibacterial drug design. Based on the crystal structure of MurD cocrystallized with thiazolidine-2,4-dione inhibitor I, we have designed, synthesized, and evaluated a series of improved glutamic acid containing 5-benzylidenerhodanine and 5-benzylidenethiazolidine-2, 4-dione inhibitors of MurD with IC50 values up to 28 μM. Inhibitor 37, with an IC50 of 34 μM, displays a weak antibacterial activity against S. aureus ATCC 29213 and E. faecalis ATCC 29212 with minimal inhibitory concentrations of 128 μg/mL. High-resolution crystal structures of MurD in complex with two new inhibitors (compounds 23 and 51) reveal details of their binding modes within the active site and provide valuable information for further structure-based optimization.